Discovery of a new blindness gene

The discovery by a Leeds University scientist of a new blindness gene could help to save the sight of thousands of sufferers of retinal disease which affects premature babies as well as people over 60.

By improving our understanding of vascular development, the breakthrough could also shed light on other diseases including tumour formation and arthritis.

Carmel Toomes, member of the Leeds vision research group, said the work could lead to early diagnosis of diseases affecting the light-sensitive part of the eye which cause the majority of cases of blindness and visual disability in the UK.

Thanks to her gene discovery, Dr Toomes has begun a Royal Society research fellowship which will enable her to continue the research for at least another five years.

“The effects of blindness can be devastating,” she said. “It is very frightening to imagine how your life would change if you were to lose your sight, but for many this is a reality. By the time we retire, one in 50 of us will have a significant defect of vision and after retirement the incidence rises sharply.”

Although retinal disease is mostly untreatable, and sight can rarely be restored once vision loss has occurred, it can sometimes be prevented if a patient is diagnosed early enough.

Dr Toomes is using genetics to understand the disease. While there are many different causes for the various types of retinal blindness, the cellular processes involved are often similar.

The group is studying rare inherited forms of retinal disease in order to understand the more common forms of blindness affected by the growth of abnormal blood vessels in diabetic retinopathy and ageing-macular dystrophy – the leading causes of blindness in the western world. The research should lead to the development of new treatments for these conditions.

The discovery of the new blindness gene was reported in the American Journal of Human Genetics.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
CRISPR-based therapy shown to be safe, effective for people with transthyretin amyloidosis